Infectious diseases caused by mucosal pathogens continue to pose a threat to humans across the globe. While vaccinations are continually being developed to provide immunity to these diseases, major advances are primarily being made with injectable vaccinations. While these advances are beneficial, many issues with injectable vaccinations still need to be addressed. Primarily, injectable vaccinations are not stable long-term and must be stored in ultra-cold freezers. Additionally, injectable vaccinations produce a systemic immune response, but lack a strong local response at the site of infection for many infectious diseases. Outer Membrane Vesicles (OMVs), biological nanoparticles derived from the cellular membrane of bacteria, may be the key to providing a strong local immune response when administered at the mucosa. OMVs contain antigens present on the surface of the bacterial cell membrane, which have been shown to promote an improved T-cell mediated immune response compared to traditional vaccinations. We hypothesize that OMVs can be suspended in a thin film matrix that is stable at room temperature and delivered via the mucosa to produce a heightened response at the mucosal membrane, resulting in strong protection against infectious diseases. Currently, research is being done to optimize the thin film formulation to produce a stable matrix at room temperature. Different ratios of polymers and solutions produce thin films with vastly different properties. Our ideal thin film formulation prevents the degradation of OMVs at room temperature, while maintaining high biocompatibility for optimal delivery via the mucosa.